IGF-I R Protein, Cynomolgus (HEK293, His)

The IGF-I R protein is a receptor tyrosine kinase that mediates the effects of insulin-like growth factor 1 (IGF1) and has high affinity for IGF1. Upon ligand binding, IGF1R is activated, leading to autophosphorylation and tyrosine phosphorylation of substrates, including IRS1/2, Shc, and 14-3-3 proteins. IGF-I R Protein, Cynomolgus (HEK293, His) is the recombinant cynomolgus-derived IGF-I R protein, expressed by HEK293 , with C-His labeled tag.

For research use only. We do not sell to patients.
  • Species: Cynomolgus
  • Source: HEK293
  • Storage:
    Stored at -20°C for 2 years from date of receipt. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.
  • Biological Activity
  • Technical Parameters
  • Product Properties
  • Documentation
  • Help & FAQs

Biological Activity

Description

The IGF-I R protein is a receptor tyrosine kinase that mediates the effects of insulin-like growth factor 1 (IGF1) and has high affinity for IGF1. Upon ligand binding, IGF1R is activated, leading to autophosphorylation and tyrosine phosphorylation of substrates, including IRS1/2, Shc, and 14-3-3 proteins. IGF-I R Protein, Cynomolgus (HEK293, His) is the recombinant cynomolgus-derived IGF-I R protein, expressed by HEK293 , with C-His labeled tag.

Background

The IGF-I R protein, a receptor tyrosine kinase, serves as a mediator for the actions of insulin-like growth factor 1 (IGF1). It exhibits a high affinity for IGF1, lower affinity for IGF2, and insulin (INS). Activation of IGF1R plays a pivotal role in controlling cell growth and survival, with critical implications in tumor transformation and the survival of malignant cells. Upon ligand binding, the receptor kinase is activated, leading to autophosphorylation and the tyrosine phosphorylation of various substrates, including insulin-receptor substrates (IRS1/2), Shc, and 14-3-3 proteins. Phosphorylation of IRS proteins initiates two main signaling pathways: the PI3K-AKT/PKB pathway and the Ras-MAPK pathway. Activation of the MAPK pathway enhances cellular proliferation, while activation of the PI3K pathway inhibits apoptosis and stimulates protein synthesis. Furthermore, IGF1R signals through the Janus kinase/signal transducer and activator of transcription pathway (JAK/STAT), where phosphorylation of JAK proteins can activate STAT proteins, particularly STAT3, contributing to the transforming activity of IGF1R. Additionally, IGF1R activates JNK kinases and exerts inhibitory effects on JNK activation. When forming a hybrid receptor with INSR, IGF1R binds IGF1.

Technical Parameters

  • Species Cynomolgus
  • Source HEK293
  • Tag C-6*His
  • Accession
  • Gene ID
  • Molecular Construction
    • N-term
    • IGF-I R (E31-N908)
      Accession # G7P9I7
    • 6*His
    • C-term
  • Protein Length

    Partial

  • Synonyms

    IGF1R; IGF-I Receptor; Insulin Like Growth Factor 1 Receptor; MGC18216; Insulin-Like Growth Factor 1 Receptor; Insulin-Like Growth Factor I Receptor; JTK13; Receptor Protein-Tyrosine Kinase; CD221; Tyrosine-Protein Kinase Receptor; IGFIR; CD221 Antigen; I

  • AA Sequence

    EICGPGIDIRNDYQQLKRLENCTVIEGYLHILLISKAEDYRSYRFPKLTVITEYLLLFRVAGLESLGDLFPNLTVIRGWKLFYNYALVIFEMTNLKDIGLYNLRNITRGAIRIEKNADLCYLSTVDWSLILDAVSNNYIVGNKPPKECGDLCPGTMEEKPMCEKTTINNEYNYRCWTTNRCQKMCPSACGKRACTENNECCHPECLGSCSAPDNDTACVACRHYYYAGVCVPACPPNTYRFEGWRCVDRDFCANILSAESSDSEGFVIHDGECMQECPSGFIRNGSQSMYCIPCEGPCPKVCEEEKKTKTIDSVTSAQMLQGCTIFKGNLLINIRRGNNIASELENFMGLIEVVTGYVKIRHSHALVSLSFLKNLRLILGEEQLEGNYSFYVLDNQNLQQLWDWDHRNLTIKAGKMYFAFNPKLCVSEIYRMEEVTGTKGRQSKGDINTRNNGERASCESDVLHFTSTTTWKNRIIITWHRYRPPDYRDLISFTVYYKEAPFKNVTEYDGQDACGSNSWNMVDVDLPPNKDVEPGILLHGLKPWTQYAVYVKAVTLTMVENDHIRGAKSEILYIRTNASVPSIPLDVLSASNSSSQLIVKWNPPSLPNGNLSYYIVRWQRQPQDGYLYRHNYCSKPTIDEEVGPCCACPKTEAEKQAEKEEAEYRKVFENFLHNSIFVPRPERKRRDVMQVANTTMSSRSRNTTVADTYNITDLEELETEYPFFESRVDNKERTVISNLRPFTLYRIDIHSCNHEAEKLGCSASNFVFARTMPAEGADDIPGPVTWEPRPENSIFLKWPEPENPNGLILMYEIKYGSQVEDQRECVSRQEYRKYGGAKLNRLNPGNYTARIQATSLSGNGSWTDPVFFYVQAKTGYEN

  • Predicted Molecular Mass

    80.6 kDa (alpha subunit) & 19.3 kDa (beta subunit)

  • Molecular Weight

    Approximately 48-58 kDa (beta subunit) & 100-115 kDa (alpha subunit) & 130-150 kDa, based on SDS-PAGE under reducing conditions, due to the glycosylation.

  • Glycosylation

    Yes

  • Purity

    ≥ 90%, as determined by reducing SDS-PAGE.

Product Properties

Appearance

Lyophilized powder.

Endotoxin Level

<1 EU/μg, determined by LAL method.

Reconstitution

It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH2O.

Storage & Stability

Stored at -20°C for 2 years from date of receipt. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.

Shipping

Room temperature in continental US; may vary elsewhere.

Calculators

Reconstitution Calculator

Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration

Volume (to add to vial) Volume (to add to vial)
=
Mass (in vial) Mass (in vial)
÷
Desired Reconstitution Concentration Desired Reconstitution Concentration
Dilution Calculator

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

Concentration (start) Concentration (start)
×
Volume (start) Volume (start)
=
Concentration (final) Concentration (final)
×
Volume (final) Volume (final)
The Specific Activity Calculator Equation
  • Specific Activity (Unit/mg)
  • Biological Activity (ED50)

Specific Activity (Unit/mg) = 106 ÷ Biological Activity (ED50)

Specific Activity (Unit/mg) Specific Activity (Unit/mg)
Unit/mg
= 106 ÷
Biological Activity (ED50) Biological Activity (ED50)
106 ÷
ng/mL
MOQ
Minimum order quantity
100 mg

Get Quote In-stock

Other size
Get Quote
Please select quantity
Amount: USD 0.00